Pfizer CEO sees no real future for Clinton's drug-pricing proposals

Ian Read

Pfizer ($PFE) CEO Ian Read isn't too worried about proposals to crack down on U.S. drug pricing. Presidential candidate Hillary Clinton's slate of new measures--which include negotiating power for Medicare--aren't likely to pass muster in Congress, Read told Evercore ISI analyst Mark Schoenebaum. After all, President Obama wanted to give such powers to Medicare, but couldn't push the change through Congress, even when Democrats controlled both houses, Read noted. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.